Furthermore, in multiple advanced drug-resistant breast cancer models, the integrated application of PFKFB3 inhibitors and ER+ targeted therapies demonstrate high efficacy in overcoming chemoresistance, including TAM and PTX (Truong et al. 2021). This evidence concerns the gene PFKFB3 and breast carcinoma.